Regulatory Core
监管核心
基本信息
- 批准号:10668165
- 负责人:
- 金额:$ 22.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-16 至 2028-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAnimal ModelAnimalsAuthorization documentationBiological ProductsCell TherapyCellular AssayClinical TrialsClinical assessmentsClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsCommunicationConsensusDataDevelopmentDocumentationElementsEligibility DeterminationEnsureFeedbackFoundationsGenerationsGenomeGoalsHumanImmune responseIndividualInheritedKnowledgeMeasuresMedicalMonitorOutcomePharmacologic SubstancePreclinical TestingRare DiseasesRecommendationRegenerative MedicineRegulatory AffairsReportingResearch Project GrantsResourcesRetinaRiskSafetySomatic CellStandardizationStrategic PlanningSystemTechnologyTestingTherapeuticToxicologyTranslational ResearchVisionWorkauthorityclinical translationexperiencefirst-in-humangene therapygenome editinghuman pluripotent stem cellimprovedmeetingspre-Investigational New Drug meetingpre-clinicalpreclinical developmentproduct developmentprogramsresearch clinical testingrisk mitigationsmall moleculestem cell modelsuccesssynergismtherapeutic developmenttherapy developmenttimeline
项目摘要
PROJECT SUMMARY/ABSTRACT - REGULATORY CORE
The objectives of this Core are to develop appropriate project-specific regulatory strategies, define project
milestones relative to the critical regulatory issues, and support execution of those strategies to meet the requisite
milestones. Genome editing technologies have several unique regulatory challenges within a rapidly changing
regulatory landscape. While the FDA provides resources to guide preclinical development, these materials
generally require a degree of applicable experience for effective and appropriate interpretation and use. The
Core staff’s substantial development experience, spanning discovery through clinical evaluation of advanced
therapeutics like cell and gene therapies, is integral to project success. The Core will leverage the Forward BIO
Institute’s Catapult Program, which employs a milestone-driven approach to support regulatory-informed
decisions and improve the pace and quality of preclinical development. Catapult focuses on navigating the
regulatory landscape during preclinical development and provides a workflow with an actionable toolkit to identify
and develop measures to address risk. The Core’s Tasks are: 1) identify critical regulatory-related deficiencies,
2) develop a comprehensive project-specific technology maturation pipeline in collaboration with the other Cores
and individual Project teams, 3) monitor progress related to regulatory milestones, and 4) develop documentation
needed to advance a therapy towards IND submission. Successful completion of these Tasks will bridge critical
knowledge gaps, mitigate risk, address regulatory concerns, and facilitate effective communication with the FDA.
Outcomes include a regulatory plan that delineates specific actions, identification of applicable FDA Expedited
Programs, and generation of documents including the INTERACT and pre-IND briefing packages and the IND
submission. The Regulatory Core will capitalize on the CRISPR Vision Program’s unique opportunity to advance
clinical translation of these modular editing and delivery systems by standardizing preclinical testing approaches,
including use of human pluripotent stem cell-based models, and by recognizing the opportunities afforded to
academic translational science by the recent FDA guidance on gene therapy for rare disease. This is possible
due to the high degree of regulatory synergy that exists between the Projects and Cores, in particular safety
aspects such as toxicology, immune response, and on/off-target effects. Numerous elements of one Project
directly inform development of the other, and sequential FDA engagement enables Projects 2 and 3 to build on
the regulatory foundation established from the feedback FDA provides to Project 1. The synergy with the Human
Cell Assay and Large Animal Cores is even more pronounced, as no suitable animal model exists to evaluate
safety for these and other somatic cell genome editors. Furthermore, a modular regulatory approach leverages
the regulatory commonalities and clarifies the unique considerations, serving to expedite the path to clinical
assessment of nonviral genomic editing technologies for rare diseases and the field as a whole.
项目摘要/摘要-监管核心
这个核心的目标是制定适当的特定于项目的监管战略,定义项目
与关键监管问题相关的里程碑,并支持执行这些战略,以满足必要的
里程碑。基因组编辑技术在快速变化的环境中面临着几个独特的监管挑战
监管格局。虽然FDA提供了指导临床前开发的资源,但这些材料
通常需要一定程度的适用经验才能有效和适当地进行解释和使用。这个
核心员工丰富的开发经验,通过对高级
像细胞和基因治疗一样,治疗是项目成功不可或缺的一部分。核心将利用前卫的传记
研究所的弹射计划,采用里程碑驱动的方法来支持监管信息
并提高临床前开发的速度和质量。Catapult专注于导航
并提供了一个带有可操作工具包的工作流程,以确定
并制定应对风险的措施。该核心的任务是:1)确定与监管相关的关键缺陷,
2)与其他核心合作开发全面的具体项目技术成熟管道
和单个项目团队,3)监控与法规里程碑相关的进度,4)开发文档
需要向IND屈服推进一种治疗方法。成功完成这些任务将起到至关重要的桥梁作用
知识差距,降低风险,解决监管问题,并促进与FDA的有效沟通。
结果包括描述具体行动的监管计划,加快确定适用的FDA
方案和文件的生成,包括InterAct和Pre-IND简报包以及IND
呈件。监管核心将利用CRISPR愿景计划的独特机会来推进
通过标准化临床前测试方法对这些模块化编辑和交付系统进行临床翻译,
包括使用基于人类多能干细胞的模型,并通过认识到为
学术翻译科学由FDA最近对罕见疾病的基因治疗指导。这是可能的
由于项目和核心之间存在高度的监管协同,特别是安全
毒理学、免疫反应和靶上/靶外效应等方面。一个项目的多个要素
直接通知其他项目的开发,FDA的顺序参与使项目2和3能够在此基础上进行构建
根据FDA向项目1提供的反馈建立的监管基础。与人类的协同作用
细胞分析和大动物核心更加明显,因为没有合适的动物模型来评估
这些和其他体细胞基因组编辑的安全性。此外,模块化的监管方法利用
监管的共性并澄清了独特的考虑因素,有助于加快临床进程
评估针对罕见疾病和整个领域的非病毒基因组编辑技术。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cathy Rasmussen其他文献
Cathy Rasmussen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cathy Rasmussen', 18)}}的其他基金
StrataScreenSENS, Skin Sensitizer Detection in Luminescent 3D Human Skin Models
StrataScreenSENS,发光 3D 人体皮肤模型中的皮肤致敏剂检测
- 批准号:
8393318 - 财政年份:2012
- 资助金额:
$ 22.97万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 22.97万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 22.97万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 22.97万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 22.97万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 22.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 22.97万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 22.97万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 22.97万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 22.97万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 22.97万 - 项目类别:
Grant-in-Aid for Early-Career Scientists